2023 - Research.com Psychology in Australia Leader Award
His scientific interests lie mostly in Alzheimer's disease, Dementia, Internal medicine, Cognitive decline and Psychiatry. David Ames has researched Alzheimer's disease in several fields, including Apolipoprotein E, Neuroscience and Episodic memory. His studies in Dementia integrate themes in fields like White matter, Gerontology and Clinical psychology.
He interconnects Intervention, Cohort study and Cohort in the investigation of issues within Gerontology. His Internal medicine research incorporates elements of Endocrinology and Oncology. David Ames combines subjects such as Prospective cohort study, Surgery, Cognition, Neuropsychological test and Pediatrics with his study of Cognitive decline.
David Ames focuses on Dementia, Disease, Internal medicine, Psychiatry and Gerontology. David Ames has included themes like Neuropsychology, Clinical psychology, Alzheimer's disease, Prospective cohort study and Cohort in his Dementia study. As a part of the same scientific family, he mostly works in the field of Alzheimer's disease, focusing on Cognitive decline and, on occasion, Cognition.
His research is interdisciplinary, bridging the disciplines of Neuroscience and Disease. His Internal medicine research includes themes of Endocrinology and Oncology. His Depression and Geriatrics study are his primary interests in Psychiatry.
David Ames mainly investigates Disease, Cognition, Dementia, Internal medicine and Alzheimer's disease. The concepts of his Disease study are interwoven with issues in Genetic heterogeneity, Gerontology, Cohort and Clinical psychology. His Cognition research is multidisciplinary, incorporating perspectives in Audiology and Cognitive decline.
His work deals with themes such as Longitudinal study, Nursing, Severity of illness, Spouse and Atrophy, which intersect with Dementia. The study incorporates disciplines such as Endocrinology and Oncology in addition to Internal medicine. His research integrates issues of Biomarker and Positron emission tomography in his study of Alzheimer's disease.
His primary areas of investigation include Alzheimer's disease, Internal medicine, Dementia, Disease and Cognition. His study in Alzheimer's disease is interdisciplinary in nature, drawing from both Amyloid beta, Biomarker, Positron emission tomography, Amyloid and Risk factor. The various areas that David Ames examines in his Internal medicine study include Oncology and Episodic memory.
His Dementia research includes themes of Longitudinal study, Gerontology, Intervention, Severity of illness and Atrophy. His Disease study combines topics from a wide range of disciplines, such as Blood proteins, Effects of sleep deprivation on cognitive performance and Clinical psychology. The concepts of his Cognition study are interwoven with issues in Evolutionary biology, Genetics, Heritability and Cortex.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Dementia prevention, intervention, and care
Gill Livingston;Gill Livingston;Andrew Sommerlad;Vasiliki Orgeta;Sergi G Costafreda;Sergi G Costafreda.
The Lancet (2017)
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.
Gill Livingston;Gill Livingston;Jonathan Huntley;Andrew Sommerlad;Andrew Sommerlad;David Ames.
The Lancet (2020)
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Victor L. Villemagne;Samantha Burnham;Pierrick Bourgeat;Belinda M. Brown.
Lancet Neurology (2013)
Metal-Protein Attenuation With Iodochlorhydroxyquin (Clioquinol) Targeting Aβ Amyloid Deposition and Toxicity in Alzheimer Disease: A Pilot Phase 2 Clinical Trial
Craig W Ritchie;Ashley I Bush;Andrew J Mackinnon;Steve Macfarlane.
JAMA Neurology (2003)
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Christopher C Rowe;Kathryn A Ellis;Kathryn A Ellis;Miroslava Rimajova;Pierrick Bourgeat.
Neurobiology of Aging (2010)
Longitudinal Assessment of Aβ and Cognition in Aging and Alzheimer Disease
Victor L Villemagne;Kerryn E Pike;Gaël Chételat;Kathryn A Ellis.
Annals of Neurology (2011)
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease
Kathryn A Ellis;Ashley I Bush;David Darby;Daniela De Fazio.
International Psychogeriatrics (2009)
Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
Lars Lannfelt;Kaj Blennow;Henrik Zetterberg;Stellan Batsman.
Lancet Neurology (2008)
Common genetic variants influence human subcortical brain structures.
Derrek P. Hibar;Jason L. Stein;Jason L. Stein;Miguel E. Renteria;Alejandro Arias-Vasquez.
A Randomized Placebo-Controlled Trial of Risperidone for the Treatment of Aggression, Agitation, and Psychosis of Dementia
Henry Brodaty;David Ames;John Snowdon;Michael Woodward.
The Journal of Clinical Psychiatry (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: